BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

Biomarker analyses show robust increases in cerebrospinal fluid neuroprotective biomarkers following NurOwn treatment

NEW YORK, Oct. 20, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that a scientific abstract titled 'NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held from October 26-28th in Amsterdam, NL.

Cerebrospinal fluid (CSF) biomarker analyses from the phase 2 progressive MS clinical trial demonstrate that intrathecal NurOwn treatment resulted in robust increases in CSF neuroprotective biomarkers, consistent with the proposed mechanism of action, and provide important biological context for the observed clinical trial outcomes.

The poster will be presented by Jeffrey Cohen, MD, Hazel Prior Hostetler Endowed Chair and Professor of Neurology, Cleveland Clinic Lerner College of Medicine, Director, Experimental Therapeutics, Mellen Center for MS Treatment and Research.

Presentation Details:

NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers
Presenter: Jeffrey Cohen, MD
Session Title: Poster Session 2
Session Date: 27.10.2022
Presenting Time: 17:00 h. Central European Time
Poster Number: P721 (link to published abstracts)